The company has launched its latest serotype-specific version of their proprietary AAV-Tek AEX Buffer Screening Kit for AAV6, along with a suite of reagents
Alpha Teknova, producer of critical reagents for the research, discovery, development, and commercialisation of novel therapies, vaccines, and molecular diagnostics, has launched the latest serotype-specific version of their proprietary AAV-Tek AEX Buffer Screening Kit for AAV6, along with a suite of reagents to support every step of the plasmid production workflow.
“Our team is relentlessly focused on developing solutions that specifically address the needs of our customers. Our latest products demonstrate our focus on addressing key bioprocessing bottlenecks and manufacturing inefficiencies during process development,” said Stephen Gunstream, Teknova’s President and CEO. “We’re committed to fulfilling our goal of becoming a true single-source partner for our customers across multiple AAV gene therapy constructs and related industry workflows."
Gunstream continued: "With today’s launch of our AAV-Tek AEX Buffer Screening Kit for AAV6, we now support three different serotypes (including AAV2 and AAV8) during downstream processing, with more to come. In addition, we offer more than 60 off-the-shelf reagents to help expedite plasmid production and purification. By making it fast and easy to get the exact solution they need at every step along the way, our customers are able to focus on the science and get into the clinic faster.”
With today’s launch of our AAV-Tek AEX Buffer Screening Kit for AAV6, we now support three different serotypes (including AAV2 and AAV8) during downstream processing
- Stephen Gunstream, Teknova's CEO
The first-of-its-kind AAV-Tek AEX Buffer Screening Kit helps AAV gene therapy developers identify the ideal buffer formulation for use during AAV downstream processing, specifically during the anion exchange (AEX) purification step. Every version of the kit includes a unique selection of serotype-specific equilibration and elution buffers designed to optimise the separation of empty and full capsids during polishing and can save AAV gene therapy developers months of process development time.
Teknova is also introducing an extensive suite of high-quality off-the-shelf reagents to support the end-to-end plasmid workflow process, from culture media to buffers and reagents for use throughout the pDNA growth and purification process.
With solutions available for selection and culturing, as well as purification and recovery, Teknova has more than 60 existing formulations to help customers expedite plasmid production to ensure reproducibility and scalability throughout the discovery and commercialisation process.
Through the combination of new, proprietary products alongside off-the-shelf reagents that enable bioprocessing workflows, Teknova continues to be uniquely positioned as a multi-platform, single-source partner for customers in cell and gene therapy, molecular diagnostics, and synthetic biology, particularly as they scale from process development to clinical-stage production.